Notable roles of EZH2 and DNMT1 in epigenetic dormancy of the SHP1 gene during the progression of chronic myeloid leukaemia

Wang,Jing; Hua,Luoming; Guo,Ming; Yang,Lin; Liu,Xiaojun; Li,Yanmeng; Shang,Xiaoyan; Luo,Jianmin

doi:10.3892/ol.2017.6050

Notable roles of EZH2 and DNMT1 in epigenetic dormancy of the SHP1 gene during the progression of chronic myeloid leukaemia

Authors:
- Jing Wang
- Luoming Hua
- Ming Guo
- Lin Yang
- Xiaojun Liu
- Yanmeng Li
- Xiaoyan Shang
- Jianmin Luo
View Affiliations

Affiliations: Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China, Department of Hematology, Affiliated Hospital of Hebei University, Baoding, Hebei 071000, P.R. China, Clinical Medicine College of Hebei University, Baoding, Hebei 071000, P.R. China
Published online on: April 19, 2017 https://doi.org/10.3892/ol.2017.6050
Pages: 4979-4985

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor development is associated with the methylation of cytosine-guanine (CpG) islands. The occurrence of methylation requires several factors, such as DNA methylation systems and polycomb group (PcG) proteins. At present, novel drugs are needed for the treatment of chronic myeloid leukaemia (CML), particularly considering the current prognosis of CML. The methylation status of the Src homology 2 domain‑containing tyrosine phosphatase 1 (SHP1) gene, a negative regulator of signal transduction, has been identified as being altered in numerous haematological malignancies. DNA methyltransferase 1 (DNMT1) and the PcG protein complex member enhancer of zeste homolog 2 (EZH2) participate in a number of gene methylation processes. The present study investigated the methylation status of the SHP1 gene in CML, and examined the association between DNMT1 and EZH2 activity and the SHP1 gene methylation status to develop novel strategies for the treatment of CML. The results revealed that SHP1 gene methylation status was altered during the progression of CML. These data indicated that SHP1 gene methylation is associated with the progression of this disease. The associations of DNMT1 and EZH2 activities with the methylation status of the SHP1 gene were additionally investigated via chromatin immunoprecipitation. DNMT1 and EZH2 were revealed to be bound to the promoter region of the SHP1 gene, and were involved in the process of SHP1 methylation. Furthermore, DNMT1 and EZH2 were associated with disease progression. Thus, the findings of the present study suggest a new target for the treatment of CML, particularly for future drug development.

View Figures

View References

1	Cools J, Maertens C and Marynen P: Resistance to tyrosine kinase inhibitors: Calling on extra forces. Drug Resist Updat. 8:119–129. 2005. View Article : Google Scholar : PubMed/NCBI
2	Sato H, Oka T, Shinnou Y, Kondo T, Washio K, Takano M, Takata K, Morito T, Huang X, Tamura M, et al: Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell Leukemia/lymphoma. Am J Pathol. 176:402–415. 2010. View Article : Google Scholar : PubMed/NCBI
3	Cheng X and Blumenthal RM: Mammalian DNA methyltransferases: A structural perspective. Structure. 16:341–350. 2008. View Article : Google Scholar : PubMed/NCBI
4	Xu F, Li X, Wu L, Zhang Q, Yang R, Yang Y, Zhang Z, He Q and Chang C: Overexpression of the EZH2, RINGl and BMIl genes is common in myelodysplastic syndromes: Relation to adverse epigenetic alteration and poor prognostic scoring. Ann Hematol. 90:643–653. 2011. View Article : Google Scholar : PubMed/NCBI
5	Nagel S, Venturini L, Marquez VE, Meyer C, Kaufmann M, Scherr M, MacLeod RA and Drexler HG: Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK/T-cell lines. Mol Cancer. 9:1512010. View Article : Google Scholar : PubMed/NCBI
6	Wu X, Gong Y, Yue J, Qiang B, Yuan J and Peng X: Cooperation between EZH2, NSPc1-mediated histone H2A ubiquitination and Dnmt1 in HOX gene silencing. Nucleic Acids Res. 36:3590–3599. 2008. View Article : Google Scholar : PubMed/NCBI
7	Kanduri M, Sander B, Ntoufa S, Papakonstantinou N, Sutton LA, Stamatopoulos K, Kanduri C and Rosenquist R: A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma. Epigenetics. 8:1280–1288. 2013. View Article : Google Scholar : PubMed/NCBI
8	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
9	Qi J, Zhu YQ, Luo J, Tao WH and Zhang JM: Hypermethylation and regulation of expression of secreted frizzled-related protein genes in colorectal tumor. Zhonghua Zhong Liu Za Zhi. 29:842–845. 2007.(In Chinese). PubMed/NCBI
10	Reddy J, Shivapurkar N, Takahashi T, Parikh G, Stastny V, Echebiri C, Crumrine K, Zöchbauer-Müller S, Drach J, Zheng Y, et al: Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene. 24:732–736. 2005. View Article : Google Scholar : PubMed/NCBI
11	Migone TS, Cacalano NA, Taylor N, Yi T, Waldmann TA and Johnston JA: Recruitment of SH2 containing protein tyrosinephosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I transformedT cells. Proc Natl Acad Sci USA. 95:pp. 3845–3850. 1998; View Article : Google Scholar : PubMed/NCBI
12	Uhm KO, Lee ES, Lee YM, Park JS, Kim SJ, Kim BS, Kim HS and Park SH: Differential methylation pattern of ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic myeloid leukemia. J Korean Med Sci. 24:493–497. 2009. View Article : Google Scholar : PubMed/NCBI
13	Chase A and Cross NC: Aberrations of EZH2 in cancer. Clin Cancer Res. 17:2613–2618. 2011. View Article : Google Scholar : PubMed/NCBI
14	He IJ, Cai MY, Xu GL, Li JJ, Weng ZJ, Xu DZ, Luo GY, Zhu SL and Xie D: Prognostic significance of overexpression of EZH2 and H3k27me3 proteins in gastric cancer. Asian Pac J Cancer Prev. 13:3173–3178. 2012. View Article : Google Scholar : PubMed/NCBI
15	McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, van Aller GS, Liu Y, Graves AP, Pietra A Della III, Diaz E, et al: EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 492:108–112. 2012. View Article : Google Scholar : PubMed/NCBI
16	Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, et al: Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood. 114:2733–2743. 2009. View Article : Google Scholar : PubMed/NCBI
17	Simon JA and Lange CA: Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. 647:21–29. 2008. View Article : Google Scholar : PubMed/NCBI
18	Cao R, Tsukada Y and Zhang Y: Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell. 20:845–854. 2005. View Article : Google Scholar : PubMed/NCBI
19	Wilson BG, Wang X, Shen X, McKenna ES, Lemieux ME, Cho YJ, Koellhoffer EC, Pomeroy SL, Orkin SH and Roberts CW: Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell. 18:316–328. 2010. View Article : Google Scholar : PubMed/NCBI
20	Bracken AP, Dietrich N, Pasini D, Hansen KH and Helin K: Genome-wide mapping of polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 20:1123–1136. 2006. View Article : Google Scholar : PubMed/NCBI
21	Kuser-Abali G, Alptekin A and Cinar B: Overexpression of MYC and EZH2 cooperates to epigenetically silence MST1 expression. Epigenetics. 9:634–643. 2014. View Article : Google Scholar : PubMed/NCBI
22	Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, van Eynde A, Bernard D, Vanderwinden JM, et al: The polycomb group protein EZH2 directly controls DNA methylation. Nature. 439:871–874. 2006. View Article : Google Scholar : PubMed/NCBI
23	Nishioka C, Ikezoe T, Yang J, Udaka K and Yokoyama A: Imatinib causes epigenetic alterations of PTEN gene via upregulation of DNA methyltransferases and polycomb group proteins. Blood Cancer J. 1:e482011. View Article : Google Scholar : PubMed/NCBI
24	Chen JH: Epigenetic studies of mesenchymal and B-cell leukemia. Beijing: Chinese Academy of Medical Sciences, Peking Union Medical College; 2010
25	Sharma A, Heuck CJ, Fazzari MJ, Mehta J, Singhal S, Greally JM and Verma A: DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. Wiley Interdiscip Rev Syst Biol Med. 2:654–669. 2010. View Article : Google Scholar : PubMed/NCBI
26	Witzig TE, Hu G, Offer SM, Wellik LE, Han JJ, Stenson MJ, Dogan A, Diasio RB and Gupta M: Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: Implications for epigenetic therapy. Leukemia. 28:147–154. 2014. View Article : Google Scholar : PubMed/NCBI
27	Chen X, Fu R, Wang Y, Song W, Ruan E, Qu W, Wang H, Wang G, Song J, Wang X, et al: Plasma DNA methylation of shp1 in patients with diffuse large B cell lymphoma. Zhonghua Yi Xue Za Zhi. 94:1071–1075. 2014.(In Chinese). PubMed/NCBI